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We present a mathematical model developed to reproduce the immune response entitled with the combined administration
of activated OT1 cytotoxic T lymphocytes (CTLs) and Anti-CD137 monoclonal antibodies. The treatment is directed against
melanoma in B16 OVA mouse models exposed to a speciﬁc immunotherapy strategy. We model two compartments: the injection
point compartment where the treatment is administered and the skin compartment where melanoma tumor cells proliferate. To
model the migration of OT1 CTLs and antibodies from the injection to the skin compartment, we use delay diﬀerential equations
(DDEs). The outcomes of the mathematical model are in good agreement with the in vivo results. Moreover, sensitivity analysis
of the mathematical model underlines the key role of OT1 CTLs and suggests that a possible reduction of the number of injected
antibodies should not aﬀect substantially the treatment eﬃcacy.
1.Introduction
Melanoma is a malignant tumor caused by the mutation of
melanocytes, that is, the cells that produce the melanin and
are responsible of the color of the skin. Despite intensive
research, melanoma still represents one of the most aggres-
sive malignant cancers [1]. Many experimental approaches
are now focused on targeting cytotoxic T lymphocytes
(CTLs) against cancer. A common strategy to enable CTL
eﬃcacy against tumor is to activate na¨ ıve CTLs in vitro
through the use of cells engineered to present the tumor
antigen, and to reinject them in the host. However, even if
activated CTLs are able to inﬁltrate into tumor masses, in
most cases they remain unable to contrast cancer growth [2].
As experimental evidence suggests, tumor-inﬁltrating lym-
phocytes are rendered ineﬀective by coinhibitory molecules
expressed by tumor and stroma cells surfaces [3].
In order to gain complete rejection of tumors, injection
and stimulation of CTLs is not suﬃcient and should be,
therefore, coupled with complementary measures voted
at boosting CTLs migration inside tumor masses, and
conjugation and killing of target cells [4–6]. One way of
boosting CTLs actions is represented by stimulation through
the binding of costimulatory proteins expressed on CTLs
surface. Among possible surface proteins, Anti-CD137, also
known as 4-1BB, represents a valuable target. This protein
is expressed by multiple IS cells such as activated T, NK, B-
lymphocytes, dendritic cells and also by tumor endothelium
cells [7]. Its natural ligand (CD137L) can be found on
activated antigen-presenting cells surface [8].
The combined administration of monoclonal antibodies
speciﬁcally targeted to bind Anti-CD137 proteins and in
vitro activated-OT1 CTLs was demonstrated to be able to
preventthemelanomaformationinB16-OVAmousemodels
[7]. Moreover, the combined treatment avoided appearing
of undesired side eﬀects like the hepatotoxicity, observed
only under anti-CD137 only high-dosage treatment [9]. The
IS stimulation mechanisms of Anti-CD137 immunostimula-
tory monoclonal antibodies are multilayered and include the
improving of cytotoxicity, duplication rates, and chemotaxis
sensitivity of activated-OT1 CTLs [6, 10–12].
To reproduce the dynamics of this biological process,
ad e l a yd i ﬀerential-equation-(DDE-) based model has been
developed. The model reproduces two diﬀerent compart-
ments: the injection point compartment, where both anti-
bodies and OT1 cells are injected and the skin compartment
where melanoma develops.2 Computational and Mathematical Methods in Medicine
2.Biological Background
The in vivo experiment is carried on B16-OVA mice, mice
transduced with the chicken ovalbumin gene. The ovalbu-
min is used as a model tumor antigen. B16 melanoma cell
line was derived from an aggressive spontaneous melanoma
in pure C57BL6, and B16F10 was derived as a clonal variant
from a lung metastasis of this cell line. In tumor immunol-
ogy, these variants of melanoma are considered poorly
immunogenic in the sense that immune-mediated rejections
or growth retardations are diﬃcult to achieve.
The experimental setup is oriented to model thera-
peutic synergy between anti-CD137 monoclonal antibodies
and adoptive T cell therapy in melanoma. B16-OVA is a
poorly immunogenic murine tumor. The treatment protocol
includes a single injection of anti-CD137 mAb and adoptive
T cell transfer of OVA-speciﬁc TCR-transgenic CD8 CTLs.
In vivo experiments have been executed by Professor
MeleroandcoworkersattheUniversityofNavarra[13].Mice
are divided in ﬁve diﬀerent groups; all groups are composed
by ﬁve individuals. Each group is treated with a diﬀerent
treatment: Untreated (control) mice, mice treated with na¨ ıve
OT1 CTLs, mice treated with na¨ ıve OT1 CTLs and Anti-
CD137 monoclonal antibodies, and mice treated with in
vitro activated OT1 CTLs, mice treated with Anti-CD137
monoclonal antibodies, mice treated with in vitro activated
OT1 CTLs and Anti-CD137 monoclonal antibodies. The
experiment runs for 30 days. At day 0, all B16-OVA mice
receive one injection of melanoma malignant cells. The
therapeutic treatment used during in vivo experiments is
composed by one single boost, and it is administered at
day 3. Melanoma surface measurements (mm2) are taken at
given times for each treatment and are used to estimate the
eﬃcacy of each vaccination strategy. We note here that in
order to compare in vivo and in silico results we computed
the estimated mean surfaces entitled with the use of each
treatment. Among the tested treatments, only the combined
administration of activated OT1 CTLs and antibodies was
able to show complete depletion of the tumor burden,
whereas the other treatments remained almost ineﬀective
[13].
3.TheModel
We realized a model with two compartments in order to
reproduce the dynamics of the process. The ﬁrst compart-
ment is represented by the injection point compartment
where the treatment is administered, whereas the second one
is represented by the skin compartment where melanoma
tumor cells proliferate and where the cancer-IS competition
occurs. To this end, a system of seven delay diﬀerential
equations has been set up. The model takes into account
the following entities: injected activated OT1 CTLs (E)a n d
injected antibodies (Ab) for the injection point compart-
ment; melanoma cells (C), tumor antigens (A), activated
OT1 CTLs and antibodies that have reached the skin (Es and
As) and na¨ ıve CTLs (N) for the skin compartment. It has
also been assumed that Injected OT1 CTLs, and antibodies
move from the injection point to the skin compartment
Table 1: Model variables. Each variable describes the total number
of the related entity in the associated compartment.
Variable Description compartment
E Injected activated OT1 CTLs injection point
Ab Injected anti-CD137 antibodies injection point
C Melanoma tumor cells skin
A Tumor antigens skin
Es Activated OT1 CTLs skin
As Injected anti-CD137 antibodies skin
N Na¨ ıve CTLs skin
only. Figure 1 shows the conceptual model for the biological
problem; model entities are listed in Table 1.
(1) Activated OT1 CTLs (injection point compartment):
dE
dt
= Kin

t, p

−α11E −α8E. (1)
Equation (1) refers to ﬁrst compartment and represents
the time evolution of injected activated OT1 CTLs. In
(1), Kin(t, p) represents a known function that models the
number of inoculated entities r at the scheduled injection
time t. E cells migrate from the injection point compartment
to the skin compartment with given rates (−α11E)a n da r e
subject to natural death (−α8E).
(2) Antibodies (injection point compartment):
dAb
dt
= Kin

t,q

−α11Ab −α10Ab. (2)
Similary to (1), (2) refers to the ﬁrst compartment and
represents the time evolution of antibodies (Ab). Ab are
injected at given times t and at given quantities q, according
tothefunctionKin(t,q),andcanmigrateanddisappearfrom
thesystembynaturaldegradationatgivenrates(−α11Ab and
−α10Ab,r e s p . ) .
(3) Activated OT1 CTLs (skin compartment):
dEs
dt
= α7

As
As +k1

Es +α11E(t −τ)+α6NA− α8Es. (3)
Activated OT1 CTLs that reach the skin compartment
(Es)ar emod eledb y(3).Antibodies intheskincompartment
(As) have multiple positive eﬀects on activated OT1 CTLs
dynamics (Es). One of these eﬀects is represented by the
ability of promoting Es duplication. This is modeled through
the Holling type II function α7[As/(As + k1)]Es,w h e r eα7 is
the maximum biological duplication rate of Es and k1 is a
tuned threshold. When the number of As is high enough, the
term [As/(As+k1)] tends towards 1, thus entitling maximum
duplicationratesforEs.Thetermα11E(t−τ)isusedtomodel
migration of OT1 CTLs from the injection compartment to
the skin compartment. We suppose here that migration fromComputational and Mathematical Methods in Medicine 3
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Figure 1: Conceptual model of the biological scenario. The model is composed by two compartments: the ﬁrst compartment (bottom)
where thetreatment is administered, andthe skincompartment (top) where theimmune-system-melanoma competition occurs. Arrowsare
used to indicate the interaction between entities (i.e., the interaction between the antibodies and activated CTLs in the skin compartment),
the change of a particular condition of an entity (i.e., the activation of na¨ ıve CTLs or the migration of antibodies from a compartment
to another), the introduction and disappearing of entities (i.e., the production of newborn na¨ ıve CTLs by thymus or the disappearing of
antigens that are presented to na¨ ıve CTLs). White boxes are used to better explain the meaning of the arrows. Both antibodies (Ab)a n d
activated OT1 CTLs (E) migrate to the skin compartment. In the skin compartment, antibodies (As) stimulate duplication and inﬁltration
into tumor mass of activated OT1 CTLs (Es), which kill melanoma cells (C). Killed melanoma cells release antigens (A) that are captured by
antigen presenting cells and presented to antigen-speciﬁc na¨ ıve OT1 CTLs (N). Na¨ ıve OT1 CTLs are then stimulated to become active CTLs
(Es).
the ﬁrst compartment (E) to the second one (Es) entitles a
time delay of τ a n do c c u r sw i t hag i v e nr a t eα11.
The term α6NA models the activation of na¨ ıve CTLs
N thanks to the presence of antigens (A) released by killed
cancer cells. The biological process that explains the presence
of this term is summarized as follows. Antigenic sequences
releasedbykilledmelanomacellsmaybecapturedbyantigen
presenting cells (APC) such as macrophages and dendritic
cells. These cells process the antigens and present them
on their cellular surface to na¨ ıve CTLs (N). After this
presentation process, na¨ ıve CTLs cells may be activated, and
if some complementary biological steps are accomplished
(i.e., stimulation by cytokines released by T helper cells),
they can become able to kill tumor cells. This process is not
modeled in depth since it involves the modeling of other
entitiesthatarenotconsideredfundamentalfortheproblem.
The number of newly activated OT1 CTLs is instead directly
estimated on the basis of the quantity of released antigens.
The last term (−α8Es) is used to take into account natural
death of OT1 CTLs.4 Computational and Mathematical Methods in Medicine
(4) Melanoma cells:
dC
dt
= (α1 −α2ln(C)) ·C −α3

As +k2
As +k3

EsC. (4)
Equation (4) describes the melanoma cells (C)b e h a v i o r
in the skin compartment. The ﬁrst term ((a1 −a2ln(C)) ·C)
represents a Gompertzian growth [14], whereas the second
term denotes killing of C by activated OT1 CTLs that are
already in the skin compartment (Es). One of the most
important actions accomplished by antibodies (As)i st o
boost chemotaxis sensitivity of CTLs (Es) thus enabling
better inﬁltration into the tumor mass. This translates into
higher killing rates of melanoma cancer cells by activated
CTLs (Es). This is modeled through the term −α3[(As +
k2)/(As + k3)]EsC,w h e r eα3 is the maximum killing rate of
C by Es,a n dk2 and k3 (k2   k3) are tuned constants. When
thenumberofAs ishighenough,theterm[(As+k2)/(As+k3)]
tends towards 1, thus entitling maximum killing rates for Es.
In absence of antibodies, having k2   k3, the term translates
into −α3k2/k3 <α 3, which involves lower killing rates.
(5) Antigens:
dA
dt
= α4

α3

As +k2
As +k3

EsC

−α5A −α6NA. (5)
With (5), we describe the tumor-associated antigen (A)
dynamics. Antigens are released in the skin compartment by
killed melanoma cells (α4 ·[α3[(As +k2)/(As +k3)]EsC]) and
a r es u b j e c tt on a t u r a ld e g r a d a t i o n( −α5A). They can also be
captured by APC, which will present the antigen to na¨ ıve
CTLs. As already stated in (3), capturing of the antigen by
APC is not modeled and the number of captured antigens is
estimated on the basis of na¨ ıve CTLs (N) that are activated
by APC (−α6NA).
(6) Na¨ ıve CTLs:
dN
dt
= h(M −N) − α6NA. (6)
Equation (6) models the behavior of na¨ ıve OT1 CTLs
(N). It is supposed here that these cells are already present
in the skin compartment. The term h(M − N) is used to
model homeostasis. M is the number of circulating na¨ ıve
CTLs under safe conditions given by the leukocyte formula.
If switching of na¨ ıve CTLs to activated CTLs occurs, the
number of na¨ ıve CTLs gets lower. As a consequence of that,
the na¨ ıve population is repopulated with newborn cells and
tends towards M at a rate h. The second term (−α6NA)
models the CTLs state changing from na¨ ıve to activated (Es),
thanks to presentation of the antigen by APC.
(7) Antibodies (skin compartment):
dAs
dt
= α11Ab(t −τ) −α9AsEs −α10As. (7)
Antibodies that have reached the skin compartment (As)
are modeled and described by (7). Antibodies in the skin
compartmentaresupposedtobeproportionaltothenumber
ofantibodiesintheinjectionpointcompartment(Ab)witha
proportionality constant α11 and a time delay of τ. They also
disappear by stimulating OT1 cells activities and are subject
to a natural degradation (−α9AsEs and −α10As).
According to the considered cell populations and inter-
actions, the mathematical model can be then represented
by the following system of seven nonlinear delay diﬀerential
equations:
dE
dt
= Kin

t, p

−α11E −α8E,
dAb
dt
= Kin

t,q

− α11Ab −α10Ab,
dEs
dt
= α7

As
As +k1

Es +α11E(t − τ)+α6NA−α8Es,
dAs
dt
= α11Ab(t −τ) −α9AsEs −α10As,
dN
dt
= h(M −N) − α6NA,
dC
dt
= (α1 −α2ln(C)) · C −α3

As +k2
As +k3

EsC,
dA
dt
= α4

α3

As +k2
As +k3

EsC

−α5A − α6NA.
(8)
Since we consider mainly populations that appear in
the system as a consequence of treatment administrations
(except for melanoma and na¨ ıve CTLs), the following
Cauchy initial conditions have been set for the equations:
E(0) = 0, Ab(0) = 0, Es(0) = 0, As(0) = 0, A(0) = 0,
N(0) = M, C(0) = C0.
(9)
The physical time-step Δ(t) has been chosen equal to 8
hours, and the integration time has been then computed up
to 102·Δ(t) ≈ 33days.Thereasonofthischoiceisbiological,
and it is given by the fact that in the in vivo experiment
it is not possible to observe relevant biological phenomena
in smaller time intervals. In particular, the minimum time
required for cell division, which represents one of the most
important biological phenomena, is usually not lower than
6–8 hours [15]. This may be not true in other in vivo setups,
such as in case of allergies, where the time scale varies from
seconds to minutes.
Some parameters appearing in the equations have been
estimated from the literature (see Table 2), and from meas-
urements made during the in vivo experiment.
In particular, melanoma growth rates have been esti-
mated from diameter measurements made at diﬀerent times
in melanomas in ﬁve untreated mice. Melanomas have two
growth phases, radial and vertical [16]. The ﬁrst phase is
represented by a radial growth, in which malignant cells
grow in a radial fashion in the epidermis. At later stages,Computational and Mathematical Methods in Medicine 5
Table 2: Model parameters. The “in vivo” label refers to parameters that have been chosen according to in vivo measurements and
observations. The “Estimated” label refers to free (unknown) parameters that have been tuned.
Param. Description Value (estimate) Ref.
α1 C growth parameter (Gompertz) 0.2165 Δ(t)
−1 in vivo
α2 C shrink parameter (Gompertz) 0.01269 Δ(t)
−1 in vivo
α3 C max killing rate by Es 0.00000033 Δ(t)
−1 Estimated
α4 A release rate by Killed C 0.21 Δ(t)
−1 Estimated
α5 A natural degradation rate ln(2)/9 Δ(t)
−1 [19]
α6 Switch rate from N to Es thanks to A 0.1 Δ(t)
−1 Estimated
α7 Es max duplication rate 0.095 Δ(t)
−1 Estimated
α8 E and Es nautral death rate ln(2)/15 Δ(t)
−1 [20]
α9 Ab death rate due to stimulation of Es 0.000001 Δ(t)
−1 Estimated
α10 Ab and As natural degradation rate ln(2)/21 Δ(t)
−1 [21, 22]
α11 migration rate from injection to skin compartment 0.009 Δ(t)
−1 Estimated
h Reinjection rate of N by thymus 0.01 Δ(t)
−1 Estimated
k1 Es duplication threshold due to As 10 Estimated
k2 C-Es min. killing rate threshold 1 Estimated
k3 C-Es max. killing rate threshold 50 Estimated
M Number of N in safe conditions (leukocyte formula) 196000 in vivo
C0 Initial number of C 180000 in vivo
p No. of injected E by treatment administration 760000 in vivo
q No. of injected Ab by treatment administration 1000000 in vivo
τ Delay value 1 in vivo
most melanomas progress to the vertical growth phase, in
which the malignant cells invade the dermis and develop the
ability to metastasize. In this case, we supposed that only the
radial growth phase is involved. By supposing a disk-shaped
layout for the melanoma and having knowledge of the mean
diameter of melanoma cancer cells, the number of cancer
cells (in the observed melanomas) has been estimated for
all the measurements made. This data has been used with a
curve ﬁtting procedure to estimate the unknown parameters
needed to model the cancer growth kinetics under the
hypothesis of a Gompertzian growth for the tumor, used
successfully in our previous experience [13, 17, 18]. The
Gompertz law, which is commonly considered suitable for
describing populations growths, uses two factors: a constant
growth term and a shrink term that increases in time and is
related to antiangiogenic factors, giving as a result a sigmoid
shape to the curve. The initial number of injected cancer
cells C0, the number of injected OT1 CTLs and antibodies (p
and q), and the number of antigen-speciﬁc na¨ ıve OT1 CTLs
under safe conditions (M) have been chosen into reasonable
ranges given by in vivo measurements.
Remaining parameters have been chosen in plausible
biological ranges in such a way to reproduce the set of
experimental data for the activated OT1 CTLs + Anti-CD37
Ab combined treatment, and counterchecked against the
other vaccine scenarios taken into account (Table 2).
4. Results
To reproduce the dynamics of the model, we took into
account four treatments that have been tested in vivo:
untreated (control), in vitro activated OT1 CTLs, Anti-
CD137 monoclonal antibodies, and in vitro activated OT1
CTLs + Anti-CD137 monoclonal antibodies.
Among such treatments, only the last one (treated
with activated CTLs + Anti-CD137 monoclonal antibodies)
showed complete eradication of the tumor burden, whereas
the other treatments remained almost ineﬀective.
Entities behaviors for all the analyzed treatments are
shown in Figure 2. In absence of therapy (blue dashed line),
there is no induced immune response and thus the number
of melanoma cells grows without any intervention from IS
cells, whose plots remain ﬂat.
The same scenario arises when the Anti-CD137 mon-
oclonal antibodies treatment is administered (see Figure 2,
green dotted lines). The mechanism that triggers the IS
response is driven by the presence of activated OT1 CTLs
that can kill melanoma cells, which release antigens able to
further stimulate the IS response.
Thisfactcanbepartiallyseenifthetreatmentbasedupon
the administration of in vitro activated OT1 CTLs is used
(Figure 2, red dot-dashed lines). The Es plots show some
evidence of activated OT1 CTLs in the skin. These cells are
able to kill melanoma cells (C), which release antigens (A)
that are captured by APCs and then used to promote the
diﬀerentiation of newborn na¨ ıve CTLs (N)t oa c t i v a t e dO T 1
CTLs (Es). However, in absence of Anti-CD137 antibodies,
which promote both duplication and inﬁltration into tumor
massesofactivatedOT1CTLs,recruitmentofnewbornna¨ ıve
CTLs is too bland and tardy to stimulate an IS response able
to stop the melanoma.6 Computational and Mathematical Methods in Medicine
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Figure 2: System behavior obtained with the use of diﬀerent vaccination protocols: untreated (blue dashed line), activated OT1 CTLs (red
dot-dashed lines), Anti-CD137 monoclonal antibodies (green dotted lines), and activated OT1 CTLs + Anti-CD137 monoclonal antibodies
(black solid lines). From left to right, top to bottom: melanoma cells (C), tumor antigens (A), activated OT1 CTLs in the skin (Es), na¨ ıve
CTLs (N), antibodies in the skin (As), antibodies in the injection point (Ab), and activated OT1 CTLs in the injection point (E).Computational and Mathematical Methods in Medicine 7
Only the combined action of activated CTLs + Anti-
CD137 monoclonal antibodies is able to to contrast the
melanoma growth (see Figure 2, black solid line). In this
case, both Anti-CD137 antibodies (Ab)a n da c t i v a t e dO T 1
CTLs (E) are injected at day three and then migrate to the
skin compartment. Activated OT1 CTLs (Es)a r es t i m u l a t e d
to duplicate and to inﬁltrate into tumor masses thanks to
the presence of antibodies in the skin compartment (As). As
a consequence of this, many more melanoma cells (C)a r e
killed, and copious number of antigens (A) is released, thus
promotingtheactivationofna¨ ıveCTLs(N)t oacti vat edO T1
CTLs (Es), which further act against melanoma.
To qualitatively compare the model results with the in
vivodata,weestimated(usingthenumberofcancercells)the
melanoma surface given by the mathematical model under
the same assumptions made for estimating the Gompertz
growth parameters. We then compared the time evolution
of the melanoma surface given by the mathematical model
with the mean surface observed in the in vivo experiment
for the following cases: the untreated (control) case and
the activated CTLs + Anti-CD137 monoclonal antibodies
combined treatment case. The other cases are not presented
since they give back the same scenario observed in the
untreated case for both the experiments.
Comparison for the untreated case is shown in
Figure 3(a). As expected, since we only observe the mela-
noma growth, the mathematical model perfectly reproduces
the in vivo setup. Comparison for the combined treatment
case is shown in Figure 3(b). The mean in vivo melanoma
behavior is well reproduced by the mathematical model
that is able to quantitatively and qualitatively represent the
shape of the curve observed in the in vivo experiments.
In Figures 3(c) and 3(d), we show absolute and relative
diﬀerences between in silico and in vivo measurements
for the untreated and activated OT1 CTLs + Anti-CD137
combined treatments, respectively. Relative diﬀerences are
computed using the following metric: d(x, y) =| x − y|/
(1/2(|x|+ |y|)).
It must be noted here that the initial gap between the
mathematical model and the in vivo experiment measure-
ments visible in Figures 3(b) and 3(d) is mainly due to
the diﬀerent nature of measurements. In the simulations,
the total number of cells is always known and it is used to
estimate the melanoma surface. In the in vivo experiment,
melanoma surface is instead measured on mice skin. Even
if the injection of tumor cells is done at time 0, melanoma
needs some time to arise and become visible even if the
melanoma cells are all already present in mice.
5.SensitivityAnalysis
To understand how the system varies under diﬀerent param-
eter values, it is important to analyze the sensitivity of
the model to variation of parameters. Classical sensitivity
analysis is done usually by varying a given parameter in
reasonable ranges and keeping the other ones ﬁxed. The
results obtained are obviously dependent on the values of
the ﬁxed parameters, and diﬀerent sets of values may entitle
completely diﬀerent results.
In order to overcome the limits of classical sensitivity
analysis, many techniques have been developed. One of
these is represented by Partial rank correlated coeﬃcients
(PRCC) [23], a statistical sensitivity analysis technique,
which computes a partial correlation on rank-transformed
data between input and output values, represented in this
case by the model parameters (input) and the model entities
behaviors (output).
It important to note here that the obtained correlation
indexes do not depend on a given set of parameters, and
it is therefore possible to estimate how the variations of a
parameter may inﬂuence the results of the model, no matter
what the value of the other parameters is. PRCC returned
values varying in [−1,1] and estimated the correlation
between input and output parameters. A value near 1
suggests a high (linear) positive correlation, whereas a value
near −1 indicates a negative correlation. Values around 0
usually indicate little or no correlation.
Using this methodology in conjunction with the Latin
Hypercube Sampling (LHS), which is used to sample the
parameters’ space, we analyze the eﬀects of the input
parameters most inﬂuencing the growth of cancer cells
(C). We plot PRCCs versus the experiment time for the
most important parameters to see how the sensitivity of
parameters changes as the system dynamics progresses.
5.1. Impact Variation of the Treatment Quantities p and q
on the Number of Melanoma Cells. The two parameters p
and q refer to the number of activated OT1 eﬀector cells
(E) and Anti-CD137 antibodies (Ab) injected as a single
boost treatment against the melanoma, according to the in
vivo experiment. In Figure 4, we show the PRCC time plots
for the two parameters. As expected, just after the injection
of the treatment, both the two parameters show a negative
correlation with the number of cancer cells. It is worth to
note that p shows good correlation in particular in the ﬁrst
tendays, whereasa weakerand almost constant correlation is
relatedtoq.Thismaysuggestthattheeﬀectsofthetreatment
are mainly driven by the OT1 eﬀector cells and, even if
antibodies are needed to obtain protection (as discussed
earlier and shown in Figure 2), a reduction in their quantity
may entitle similar treatment eﬀectiveness.
5.2. Impact of Na¨ ıve OT1 CTLs Initial Number (M)a n d
Recovery Rate (h) on the Number of Cancer Cells. The M
parameter indicates the initial number of antigen-speciﬁc
na¨ ıve CTLs in the host, and the h parameter represents the
rate of newborn na¨ ıve CTLs generated by thymus selection.
The M parameter negatively correlates over time with the
number of melanoma cells (Figure 5(a)), thus conﬁrming
that the action of na¨ ıve OT1 T cells induced by the treatment
administration is fundamental for treatment eﬀectiveness.
Surprisingly it seems that the variation of the rate of
introduced newborn na¨ ıve CTLs does not inﬂuence the
number of melanoma cells, since no correlation is shown
over time (see Figure 5(b)).
5.3. Impact of Activated OT1-T-Related Parameters on the
Number of Cancer Cells. The activated OT1 CTLs in the skin8 Computational and Mathematical Methods in Medicine
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Figure 3: Comparison of melanoma surface (mm2) behavior over time between mean in vivo measurements (red lines) and simulations
(blue lines). (a) Comparison for the untreated case (no vaccination). (b) Comparison under the administration of the combined activated
OT1 CTLs + Anti-CD137 monoclonal antibodies treatment. In silico melanoma surfaces have been estimated from the total number of
melanoma cells by assuming only radial growth and a disk-shaped layout for the melanoma. (c) Absolute (orange line) and relative (green
line) diﬀerences between in vivo and in silico measurements for the untreated case (no vaccination). (d) Absolute (orange line) and relative
(green line) diﬀerences between in vivo and in silico measurements under the administration of the combined activated OT1 CTLs + Anti-
CD137 monoclonal antibodies treatment.
(Es) represent the number of entities that are directly able to
kill melanoma tumor cells. It is, therefore, trivial to see that
α3 and α8, which represent the rate of killed melanoma cells
by activated OT1 eﬀector cells and the half-life of OT1 eﬀec-
tor cells, have a strong negative and positive correlation with
the number of cancer cells, respectively, (see Figures 6(a)
and 6(b)). A negative correlation is also present for α7,
which represents the maximal duplication rate of (Es) (see
Figure 6(c)). However, in this case the correlation remains
weaker, thus suggesting how small variations on the cells
duplication rates, which can be associated with individual
diversity, do not inﬂuence considerably the total behavior of
cancer cells.
5.4. Impact of Antibody-Related Parameters on the Number
of Cancer Cells. The α4 parameter is used to represent
the rate of antigens released by killed C, whereas the α5
represents the speciﬁc antigen half-life. If the former has
a strong negative PRCC correlation with the number of
C (Figure 7(a)), particularly in the ﬁrst period just after
treatment administration, the latter interestingly seems to be
not correlated with the number of C (Figure 7(b)).Computational and Mathematical Methods in Medicine 9
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Figure 4: p (a) and q (b) PRCC plots computed on C. PRCC values are calculated with respect to the number of melanoma cells (C), plotted
over time (blue lines). PRCC time plot of Dummy parameter (red lines) is shown for comparison. Greyed areas represent the plot portions
where correlation is signiﬁcant (P<0.01).
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plotted over time (blue lines). PRCC time plot of Dummy parameter (red lines) is shown for comparison. Greyed areas represent the plot
portions where correlation is signiﬁcant (P<0.01).10 Computational and Mathematical Methods in Medicine
P
R
C
C
Time (days)
Dummy
Signiﬁcant (P<0.01)
1
0.8
0.6
0.4
0.2
0
−0.2
−0.4
−0.6
−0.8
−1
0 5 10 15 20 25 30
α3
(a) C PRCC time-plot for α3
P
R
C
C
Time (days)
Dummy
Signiﬁcant (P<0.01)
1
0.8
0.6
0.4
0.2
0
−0.2
−0.4
−0.6
−0.8
−1
0 5 10 15 20 25 30
α7
(b) C PRCC time-plot for α7
P
R
C
C
Time (days)
Dummy
Signiﬁcant (P<0.01)
1
0.8
0.6
0.4
0.2
0
−0.2
−0.4
−0.6
−0.8
−1
0 5 10 15 20 25 30
α8
(c) C PRCC time-plot for α8
Figure 6: α3 (a), α7 (b), and α8 (c) PRCC plots computed on C. PRCC values are calculated with respect to the number of melanoma cells
(C), plotted over time (blue lines). PRCC time plot of Dummy parameter (red lines) is shown for comparison. Greyed areas represent the
plot portions where correlation is signiﬁcant (P<0.01).Computational and Mathematical Methods in Medicine 11
P
R
C
C
Time (days)
Dummy
Signiﬁcant (P<0.01)
1
0.8
0.6
0.4
0.2
0
−0.2
−0.4
−0.6
−0.8
−1
0 5 1 01 52 02 53 0
α4
(a) C PRCC time-plot for α4
P
R
C
C
Time (days)
Dummy
Signiﬁcant (P<0.01)
1
0.8
0.6
0.4
0.2
0
−0.2
−0.4
−0.6
−0.8
−1
05 10 15 20 25 30
α5
(b) C PRCC time-plot for α5
Figure 7: α4 (a) and α5 (b) PRCC plots computed on C. PRCC values are calculated with respect to the number of melanoma cells (C),
plotted over time (blue lines). PRCC time plot of Dummy parameter (red lines) is shown for comparison. Greyed areas represent the plot
portions where correlation is signiﬁcant (P<0.01).
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Figure 8: α1 (a) and α2 (b) PRCC plots computed on C. PRCC values are calculated with respect to the number of melanoma cells (C),
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5.5. Impact of the Tumor Growth and Shrink Parameters (α1
andα2)ontheNumberofCancerCells. Theα1 andα2 param-
eters represent the Gompertz growth parameters used to
model the growth of melanoma. The range of variation for
these two parameters has been set equal to the conﬁdence
range given by the curve ﬁtting procedure used to estimate
the parameters’ values from in vivo measurements. In this
way, we reasonably take into account the possible melanoma
growthsthatmayalsobeobservedintheinvivoexperiments.
PRCC plots over time are represented in Figures 8(a) and
8(b). Even if positive and negative PRCC correlations are
somewhat expected, there is a small time window just after
the treatment injection time where no correlation occurs.
This may be explained by the fact that variations of the
melanomagrowthratedonotinﬂuencesubstantially(atleast
initially) the eﬀectiveness of the treatment.
6. Conclusions
We presented a mathematical model, which reproduces the
immune response against B16-melanoma induced by the
combined administration of activated OT1 CTLs and Anti-
CD 137 immunostimulatory monoclonal antibodies. The
m o d e lu s e sd e l a yd i ﬀerential equations to reproduce the
presence of two diﬀerent compartments: the injection point
compartment where the treatment is administered, and the
skin compartment, where the melanoma-Immune system
competition occurs.
The model proved to be able to coherently reproduce the
in vivo experiment results obtained with four vaccination
strategies (untreated, only activated OT1 CTLs, only mon-
oclonal Ab, OT1 CTLs + monoclonal Ab). Moreover, the
m o d e li sa b l et oq u a l i t a t i v e l ya n dq u a n t i t a t i v e l yr e p r o d u c e
the time dynamics of melanoma under the administration
of the combined treatment. Results show that activated CTLs
+ Anti-CD137 monoclonal combined treatment acts in two
ways: directly by activated OT1 CTLs that are able to kill
melanoma and antibodies that boost CTLs activities and
indirectlybypromotingactivationofna¨ ıveOT1CTLsthanks
to the releasing of melanoma cells antigens.
Among some useful ﬁndings, sensitivity analysis under-
lined the important role of activated OT1 cytotoxic treat-
ment, suggesting that it would be in principle possible to
obtain similar eﬀectiveness lowering the number of admin-
istered antibodies, which, however, remain fundamental to
gain eﬀectiveness. Such kind of suggestions may be useful for
optimizing treatment eﬀectiveness and minimizing the risk
of side eﬀects.
Future work will be focused on studying analytically
a simpliﬁed model without delay and in comparing the
obtained results with Sim-B16, an agent-based model devel-
oped to reproduce the same in vivo experiment [13].
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